Remove 2027 Remove Chemotherapy Remove Compounding
article thumbnail

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

Completion Date (Estimated): June 2027 “For people living with advanced ROS1+ lung cancer, who tend to be diagnosed at a younger age, having another treatment option can make a real difference for them and their loved ones,” Janet Freeman-Daily, cofounder and president of The ROS1ders, said in a news release.

FDA 73
article thumbnail

Jiashu Xie, PhD

Blog: Ask a Student Pharmacist

Jiashu Xie, PhD eomizowh Wed, 06/21/2023 - 10:11 Expand all + Biography Research Summary Current research in the Pharmacokinetics (PK) lab has focused on profiling the in vitro ADME (absorption, distribution, metabolism, and excretion) and in vivo PK properties of lead compounds from medicinal chemistry efforts.

article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

The FDA Law Blog

Few would oppose FDA-approved marijuana-derived medications if marijuana compounds are found to have medical value; the National Institute of Health should continue to fund research on any potential medical value of marijuana and on the harms of highly potent products.